Zobrazeno 1 - 10
of 224
pro vyhledávání: '"Wen Juei Jeng"'
Autor:
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 3, Pp 375-387 (2024)
Background/Aims Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokineti
Externí odkaz:
https://doaj.org/article/ed2aee832b8041db91c2040ffaf8a503
Autor:
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 7, Pp 788-795 (2024)
Background: Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving
Externí odkaz:
https://doaj.org/article/dd0e84d5046f46e492a2131ecc45a421
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/1a776457b3314021b2110b7623e989a8
Autor:
Yi-Ming Chen, Ching-Heng Lin, Wen-Juei Jeng, Hwai-I Yang, Yen-Ju Chen, Tzu-Hung Hsiao, Ying-Cheng Lin, Chien-Lin Mao, Chia-Yi Wei, Yi-Chung Hsieh, Chih-Jen Huang, Mei-Hung Pan, I-Chieh Chen
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objectives This study aimed to develop a predictive model using polygenic risk score (PRS) to forecast renal outcomes for adult systemic lupus erythematosus (SLE) in a Taiwanese population.Methods Patients with SLE (n=2782) and matched non-SLE contro
Externí odkaz:
https://doaj.org/article/ca10ad9fe3634f119442e8de67d2372d
Autor:
Yu-Ting Kao, Yen-Chun Liu, Ya-Ting Cheng, Yu-Wen Wen, Yi-Chung Hsieh, Cheng-Er Hsu, Chung-Wei Su, Jennifer Chia-Hung Tai, Yi-Cheng Chen, Wen-Juei Jeng, Chun-Yen Lin, Rong-Nan Chien, Dar-In Tai, I-Shyan Sheen
Publikováno v:
Viruses, Vol 16, Iss 9, p 1485 (2024)
Background: Hepatocellular carcinoma (HCC) remains a significant concern for patients with chronic hepatitis C (HCV), even after achieving a sustained virological response (SVR) with direct-acting antivirals (DAAs) or interferon (IFN)-based therapies
Externí odkaz:
https://doaj.org/article/8a1958bfb9574e1dbec7b759903364bb
Autor:
Hao-Hsuan Liu, Chieh-Li Yen, Wen-Juei Jeng, Cheng-Chieh Hung, Ching-Chung Hsiao, Ya-Chung Tian, Kuan-Hsing Chen
Publikováno v:
Diagnostics, Vol 14, Iss 18, p 2048 (2024)
BACKGROUND: Chronic hepatitis B and C infections are major causes of morbidity and mortality in end-stage kidney disease (ESKD) patients on hemodialysis (HD). The Fibrosis-4 (FIB-4) score is a non-invasive method to evaluate chronic liver disease. Ho
Externí odkaz:
https://doaj.org/article/904b04da550347bf9b100a9f29f57d72
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Low-education women, a substantially older population, are subject to increased risks of metabolic syndrome and consequent cardiometabolic diseases; early detection and effective management were urgently needed. Ninety-nine women with metabo
Externí odkaz:
https://doaj.org/article/225d7819e0424e4f9aad6ea62e29e16d
Autor:
Chung‐Wei Su, Wei Teng, Po‐Ting Lin, Wen‐Juei Jeng, Kuei‐An Chen, Yi‐Chung Hsieh, Wei‐Ting Chen, Ming‐Mo Ho, Chia‐Hsun Hsieh, Ching‐Ting Wang, Pei‐Mei Chai, Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7077-7089 (2023)
Abstract Background Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies comparison of efficacy and safety in these two regimens are limited,
Externí odkaz:
https://doaj.org/article/216f93a49f9b419c95928f65f96fe04e
Autor:
Wei Teng, Wen‐Juei Jeng, Wei‐Ting Chen, Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin, I‐Shyan Sheen
Publikováno v:
Cancer Medicine, Vol 11, Iss 20, Pp 3786-3795 (2022)
Abstract Background A soluble form of cytotoxic‐T‐lymphocyte‐antigen‐4 (sCTLA‐4) is a prognostic biomarker for several cancers but remains unclear in HCC patients. The aim of study is to evaluate the predictive role of serum sCTLA‐4 level
Externí odkaz:
https://doaj.org/article/737e1a030570431f8bc922e7b11ddd63
Autor:
Wen-Juei Jeng, Chien-Hung Chen, Yi-Wen Wang, Mei-Hung Pan, Chia-Wei Lin, Chun-Yen Lin, Hwai-I Yang
Publikováno v:
Virology Journal, Vol 19, Iss 1, Pp 1-8 (2022)
Abstract Background Soluble programmed death-1 (sPD-1) is a novel immune markers and possibly predictive of chronic hepatitis B (CHB) outcome. However, results were inconsistent by different ELISA kits. This study aims to compare the characteristics
Externí odkaz:
https://doaj.org/article/bb7ca646633748cbbc58f73715df1486